Two ChEs are reported, acetylcholinesterase (AChE) and butyrylcholinesterase (BChE).11 AChE are more expressed than BChE in the cerebral cortex and in the hippocampus of the brain, whereas, during the progress of AD, a great increase in the activity of BChE was reported.12 Based on the important roles of cholinesterase enzymes in the pathophysiology of AD, their inhibitors (AChE and BuChE inhibitors) are FDA approved for the symptomatic treatment of AD.13 This evidence concerns the gene ACHE and Alzheimer disease.